The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line

DNA and Cell Biology
Izumi NagatomoIchiro Kawase

Abstract

A specific inhibitor of the Epidermal Growth Factor Receptor (EGFR), Gefitinib, displays significant antitumor effects against non-small cell lung cancers (NSCLC) that express EGFR with mutations in their tyrosine kinase domain. Although previous reports have already demonstrated that oncogenic transformation can be induced by some mutant EGFR forms, the precise differences between mutant and wild-type EGFR in terms of mechanisms of transformation have not been fully elucidated. We show here that a murine fibroblast cell line, NR6 becomes transformed by an expression level of the mutant EGFR form lacking E746-A750 that is far less than that needed with transfected wild-type EGFR. However, the mutant EGFR was unable to transform NR6 in a ligand-independent manner, as was seen with the wild-type EGFR. The consequent biological features after transformation, including DNA synthesis or cell cycle progression and biochemical characteristics such as MAPK activation mediated by the mutant EGFR are comparable and equivalent to those mediated by wild-type EGFR. These data suggest that the mutant EGFR possesses greater ligand-dependent transformation when compared with wild-type EGFR, although the exact mechanisms to account for this cha...Continue Reading

References

Sep 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·R M Pruss, H R Herschman
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G PagèsJ Pouysségur
Nov 1, 2000·Cell·J Schlessinger
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Apr 26, 2001·Proceedings of the National Academy of Sciences of the United States of America·T KumagaiM I Greene
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R I NicholsonM E Harper
Nov 15, 2002·The New England Journal of Medicine·William C Hahn, Robert A Weinberg
Mar 22, 2003·Experimental Cell Research·Robert N JorissenAntony W Burgess
Mar 22, 2003·Experimental Cell Research·Julie L BoernerNita J Maihle
Apr 24, 2003·Cancer Science·Isamu OkamotoAlbert J Wong
May 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiro FukuokaJosé Baselga
Jul 18, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fred R HirschWilbur A Franklin
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chris A LearnJohn H Sampson
Jul 31, 2004·Science·Raffaella SordellaJeffrey Settleman
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Dec 2, 2004·Nature Reviews. Cancer·Judith S Sebolt-Leopold, Roman Herrera
Feb 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey A EngelmanLewis C Cantley
Sep 29, 2005·PLoS Medicine·Heidi GreulichMatthew Meyerson
Dec 24, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kazuko SakaiKazuto Nishio
May 26, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kok Choi KongRaymond B Penn

❮ Previous
Next ❯

Citations

Feb 24, 2007·Nature Reviews. Cancer·Sreenath V SharmaDaniel A Haber
Dec 10, 2008·Expert Opinion on Biological Therapy·Zhongdong HuangH Michael Shepard
Aug 30, 2008·Experimental Cell Research·Sreenath V Sharma, Jeffrey Settleman
Feb 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistDaniel A Haber
Dec 21, 2018·JCI Insight·Yuhei KineharaAtsushi Kumanogoh

❮ Previous
Next ❯

Related Concepts

Related Feeds